Sulanemadlin
- Generic Name
- Sulanemadlin
- Drug Type
- Biotech
- CAS Number
- 1451199-98-6
- Unique Ingredient Identifier
- 6BGF28R54M
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
- Conditions
- Prevention of Chemotherapy-induced Myelosuppression
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05622058
- Locations
- 🇧🇬
MBAL University Hospital OOD, Panagyurishte, Bulgaria
🇺🇸Southern Oncology Specialists, Huntersville, North Carolina, United States
🇺🇸Oncology and Hematology Associates of West Broward, Tamarac, Florida, United States
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
- Conditions
- Small-cell Lung CancerNon Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT04022876
- Locations
- 🇺🇸
Mount Sinai Cancer Research Program, Miami, Florida, United States
🇺🇸Regional Medical Oncolgy Center, Wilson, North Carolina, United States
🇺🇸Gabrail Cancer Institute, Canton, Ohio, United States
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
- Conditions
- LeukemiaBrain TumorSolid TumorLymphoma
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT03654716
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- Drug: ALRN-6924 in combination with cytarabine
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02909972
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT02264613
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.